Form 4: Harrow CFO Andrew Boll Granted Significant Performance-Based Equity Tied to Ambitious Stock Price Targets

Harrow, Inc.'s Chief Financial Officer, Andrew R. Boll, has been granted 405,750 performance-based restricted stock units (PSUs) under the company's 2025 Stock Incentive and Awards Plan, contingent on a three-year service period and aggressive stock price achievements.

Summary

• Andrew R. Boll, Chief Financial Officer of Harrow, Inc. (HROW), was granted 405,750 performance-based restricted stock units (PSUs).
• The grant was made on July 1, 2025, under the Issuer's 2025 Stock Incentive and Awards Plan.
• Each PSU represents a contingent right to receive one share of Harrow common stock upon vesting.
• Vesting of the PSUs requires a minimum three-year service period.
• Additional vesting conditions include the achievement and maintenance of specific Harrow common stock price targets:
• $50 stock price target: 56,805 PSU shares vest.
• $60 stock price target: 85,208 PSU shares vest.
• $75 stock price target: 117,668 PSU shares vest.
• $100 stock price target: 146,069 PSU shares vest.

Sentiment

Score: 8

Explanation: The grant of performance-based equity to a key executive, tied to ambitious stock price targets, is a strong positive signal for aligning management incentives with shareholder value creation and confidence in future growth. The targets are aggressive, indicating high expectations.

Positives

• The grant of performance-based restricted stock units aligns the Chief Financial Officer's incentives directly with shareholder value creation, as vesting is tied to significant increases in Harrow's common stock price.
• The structure encourages long-term commitment from a key executive through a minimum three-year service period requirement.
• The potential for substantial equity ownership for the CFO if ambitious stock price targets are met signals management's confidence in future growth and strategic execution.

Negatives

• The PSUs do not provide immediate liquidity or cash benefit to the CFO, as they are contingent on future performance and service.
• The stock price targets of $50, $60, $75, and $100 are aggressive and represent significant hurdles, meaning there is no guarantee of vesting for all or even a portion of the PSUs.
• Failure to meet the stock price targets or complete the service period would result in forfeiture of the unvested PSUs.

Risks

• Failure to achieve and maintain the specified common stock price targets ($50, $60, $75, $100) could result in the forfeiture of a significant portion or all of the granted PSUs.
• The Chief Financial Officer must complete a minimum three-year service period for any PSUs to vest, introducing a risk of forfeiture if employment ceases before this period.
• Market conditions and company performance may not support the ambitious stock price targets, impacting the value and vesting of the PSUs.

Future Outlook

The grant of performance-based restricted stock units indicates a forward-looking strategy to incentivize the Chief Financial Officer to drive significant increases in Harrow's common stock price, with targets set at $50, $60, $75, and $100 per share, contingent on a minimum three-year service period.

Management Comments

• The PSUs were granted under the Issuer's 2025 Stock Incentive and Awards Plan.
• Each PSU represents a contingent right to receive one share of common stock upon vesting.
• Vesting of the PSUs requires a minimum three-year service period and the achievement and maintenance of specific common stock price targets.

Industry Context

Performance-based equity compensation, such as PSUs tied to stock price targets and service periods, is a common practice in the pharmaceutical and biotechnology industries to align executive incentives with long-term shareholder value creation. This structure aims to motivate management to achieve strategic goals that translate into market capitalization growth.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) with both service and stock price hurdles is a standard and widely accepted form of executive compensation across various industries, including pharmaceuticals and healthcare.
• The specific stock price targets of $50, $60, $75, and $100 are aggressive and imply a significant expected increase in Harrow's market valuation, which is typical for growth-oriented companies aiming for substantial shareholder returns.
• While the document does not provide specific comparable companies or their compensation structures, the general approach of tying a substantial portion of executive compensation to long-term stock performance is consistent with best practices designed to align management and shareholder interests.

Corporate Governance

Related Party Transactions

• The grant of 405,750 performance-based restricted stock units to Andrew R. Boll, the Chief Financial Officer, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact as the CFO's compensation is directly tied to significant increases in the company's stock price, aligning executive interests with shareholder returns.
• Employees: No direct impact mentioned, but successful achievement of stock price targets could indicate overall company growth and success, potentially benefiting all employees.
• Management: The CFO is highly incentivized to achieve ambitious stock price targets, which could drive strategic decisions focused on growth and market value.

Next Steps

• Andrew R. Boll will continue to serve as Chief Financial Officer for a minimum three-year service period.
• Harrow, Inc. will work towards achieving and maintaining the specified common stock price targets of $50, $60, $75, and $100 to enable the vesting of the PSUs.

Key Dates

Keywords

Harrow, HROW, Andrew R. Boll, Chief Financial Officer, CFO, SEC Form 4, Performance-Based Restricted Stock Units, PSUs, Equity Compensation, Stock Incentive Plan, Executive Compensation, Beneficial Ownership, Stock Price Targets